Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Effectiveness of EV-Pure + WJ-Pure Treatment on Pulmonary Fibrosis Secondary to Covid-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05387239
Recruitment Status : Recruiting
First Posted : May 24, 2022
Last Update Posted : June 8, 2022
Sponsor:
Information provided by (Responsible Party):
Vitti Labs, LLC

Brief Summary:
The COVID-induced fibrotic lung damage continues long after viral infection has subsided and is exhibited by severe respiratory pathology and concomitant symptoms. The long-lasting sequelae in patients who have recovered from severe COVID indicate that there is a 30% chance of developing a persistent respiratory system pathology and a 10% chance of developing a severe pathology. The symptoms of lung fibrosis include a severe disruption of respiration, reduction of exercise tolerance, and concomitant development of persistent fibrotic lung damage. This study intends to evaluate benefits of a combination of WJPure and EVPure in Covid-19 patients exhibiting pulmonary fibrosis.

Condition or disease Intervention/treatment Phase
Pulmonary Fibrosis COVID-19 Respiratory Infection Drug: EV-Pure™ and WJ-Pure™ plus standard care Drug: Placebo Phase 1

Detailed Description:

Multiple clinical trials are underway to explore options for treatment of pulmonary fibrosis in patients with history of COVID. Mesenchymal stem cell (MSC)-based therapies have been used worldwide for various pulmonary diseases. A recent review of over 110 reports of clinical trials worldwide with MSC-based therapies in pulmonary diseases found that these therapies have been reported to be safe and effective in the treatment of acute/viral pulmonary disease, community-acquired pneumonia (CAP), chronic obstructive pulmonary disease (COPD), bronchopulmonary dysplasia (BPD), interstitial lung diseases (ILD), chronic pulmonary fibrosis, bronchiolitis obliterans syndrome (BOS) and lung cancer. A phase 2 clinical trial in 101 severe Covid-19 patients with lung damage using human umbilical cord derived MSCs found that the treatment exerted numerical improvement in whole lung lesion volume and the 6-minute walk test from baseline to day 28 compared with the placebo.

This proof of concept, double-blind, placebo-controlled trial will evaluate the safety and efficacy of intravenous infusion of EV-Pure™ and WJ-Pure™, versus placebo, for use in the treatment of Covid induced Pulmonary Fibrosis. This is an add-on treatment study; subjects will be allowed to take standard of care treatments available.

The study will have two arms (n=10 each):

  1. Experimental/treatment arm: EV-Pure™ and WJ-Pure™ plus standard care
  2. Placebo: Saline plus standard care

The study duration would be 5 days of treatment plus 12 weeks follow up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Effectiveness of EV-Pure + WJ-Pure Treatment on Pulmonary Fibrosis Secondary to Covid-19
Estimated Study Start Date : June 2022
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Experimental/treatment arm Drug: EV-Pure™ and WJ-Pure™ plus standard care
The treatment consists of administration of WJ-Pure™ and EV-Pure™ plus standard care

Placebo Comparator: Placebo Drug: Placebo
Saline plus standard care




Primary Outcome Measures :
  1. Evaluate incidences of Treatment-Emergent Adverse Events following following EV-Pure™ and WJ-Pure™ administeration to patients exhibiting Covid induced Pulmonary Fibrosis. [ Time Frame: 3 months ]
    Presence of adverse events in less than 10% of the study population, as a measure of safety

  2. To evaluate the efficacy of EV-Pure™ and WJ-Pure™ administration in alleviating long term symptoms of Covid induced Pulmonary Fibrosis, compared to placebo [ Time Frame: 3 months ]
    Change in distance walked on the six-minute walk test (6MWT). The 6MWT is a validated endpoint commonly used in clinical trial research.


Secondary Outcome Measures :
  1. Change in Pulse Oximetry at Rest and During the 6MWT [ Time Frame: 3 months ]
    Oxygen saturation (pulse oximetry) at rest and during the 6-minute walk test (6MWT)

  2. Incidence of Re-Hospitalization [ Time Frame: 3 months ]
    Incidence of hospitalization after initial discharge and initiating treatment

  3. Quality of Life assessment as collected using the SF-36 [ Time Frame: 3 months ]
    The SF-36 (v2) is a self-administered questionnaire containing 36 items that measures functional status, well-being, and overall evaluation of health in 8 domains.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects will be eligible for enrollment in the study only if they meet the following criteria:

    1. Male or female, aged between 25 years (including) to 90 years old
    2. Confirmed and documented COVID-19 infection history with confirmed diagnosis of Pulmonary Fibrosis
    3. Negative to current Covid-19 infection as tested by RT-PCR tests
    4. Able to perform a 6-minute walk test
    5. Blood routine, liver and kidney functions test values are within controllable range

      1. Adequate hepatic function as evidenced by ALT, AST and LDH < 2X ULN and bilirubin < 1.5X ULN for the reference lab
      2. Adequate renal function as evidenced by a serum creatinine ≤ 1.5 X ULN for the reference laboratory OR a calculated creatinine clearance of ≥ 60 mL/min by the Cockcroft-Gault Equation
      3. Adequate hematopoietic function as evidenced by white blood cells ≥ 3x109 / L and platelets ≥ 100x109 / L
    6. If childbearing age: agree to practice effective birth control from screening until 12 weeks after the last study treatment.

Exclusion Criteria:

  • Subjects will be ineligible for enrollment in the study if they meet any of the following criteria:

    1. Clinically relevant heart condition such as, but not limited to, uncontrolled heart failure, severe pulmonary hypertension, atrial fibrillation or significant congenital heart disease
    2. Severe asthma on chronic therapy with biologics or steroids
    3. Active smokers as defined as individuals who currently smokes at least one cigarette or equivalent product a day. (Ex-smokers who had regularly smoked but who had not smoked the previous month are eligible)
    4. Evidence of active malignancy, or prior history of active malignancy not in remission.
    5. Life expectancy of < 6 months
    6. Patient included in another ongoing interventional therapeutic trial.
    7. Pregnant or Lactating.
    8. Serious or life-threatening co-morbidities, that in the opinion of the investigators, may compromise the safety or compliance with the study guidelines and tracking.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05387239


Contacts
Layout table for location contacts
Contact: Mukesh Kumar 2407504893 mkumar@fdamap.com

Locations
Layout table for location information
United States, Missouri
Kit Bartalos Recruiting
Liberty, Missouri, United States, 64068
Contact: Kit Bartalos, DO         
Sponsors and Collaborators
Vitti Labs, LLC
Layout table for additonal information
Responsible Party: Vitti Labs, LLC
ClinicalTrials.gov Identifier: NCT05387239    
Other Study ID Numbers: EW-02
First Posted: May 24, 2022    Key Record Dates
Last Update Posted: June 8, 2022
Last Verified: June 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Pulmonary Fibrosis
Fibrosis
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Pathologic Processes